Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Evaluation of novel cell cycle inhibitors in mantle cell lymphoma

Oncogene volume 26, pages 5635–5642 (2007)Cite this article

Abstract

Signature abnormalities in the cell cycle and apoptotic pathway have been identified in mantle cell lymphoma (MCL), affording the opportunity to develop targeted therapies. In this study, we tested a novel class of kinase inhibitors, styryl sulfones, which differ from prior cell cycle inhibitors in that they are not related to purines or pyrimidines. We observed that two closely related compounds, ON013100 and ON01370, altered the growth and cell cycle status of MCL lines and potently inhibited the expression of several important molecules, including cyclin-dependent kinase4, p53, mouse double minute 2 (MDM2), and cyclin D as well as increased cyclin B expression. Using both terminal deoxy transferase uridine triphosphate nick end-labelling and poly ADP-ribose polymerase assays, we found that these compounds caused apoptosis in MCL cells. In addition, using molecular analyses, we observed the modulation of caspase-3 activity but not the expression of B-cell lymphoma family molecules. Next, we investigated the cytotoxicity of the MCL lines upon treatment with styryl sulfone compounds in combination with other currently used chemotherapeutic agents, such as doxorubicin (DOX) or vincristine (VCR). We found that the combination of DOX plus styryl sulfone or VCR plus styryl sulfone increased cytotoxicity by one log scale, compared with the single styryl sulfone compound. Thus, styryl sulfones alone, or in combination with chemotherapeutic agents, present attractive opportunities for new drug development in MCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. (1994). PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative discoders: a highly specified marker of mantle cell lymphoma. Blood 84: 2725–2732.

    Google Scholar 

  • Boutros R, Byrne JA . (2005). D53 (TPD52L1) is a cell cycle-regulated protein maximally expressed at the G2-M transition in breast cancer cells. Exp Cell Res 310: 152–162.

    Article  CAS  PubMed  Google Scholar 

  • Braday SC, Allan LA, Clarke PR . (2005). Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol 25: 10543–10555.

    Article  Google Scholar 

  • Brauns SC, Dealtry G, Milne P, Naude R, Van de Venter M . (2005). Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide cyclo(Phe-Pro) in HT-29 cells. Anticancer Res 25: 4197–4202.

    CAS  PubMed  Google Scholar 

  • Campo E, Raffeld M, Jaffe ES . (1999). Mantle cell lymphoma. Semin Hematol 36: 115–127.

    CAS  PubMed  Google Scholar 

  • Chiarle R, Budel LM, Skolnik J, Fizzera G, Chilosi M, Corato A et al. (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95: 619–626.

    CAS  PubMed  Google Scholar 

  • Choi S, Singh SV . (2005). Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 65: 2035–2043.

    Article  CAS  PubMed  Google Scholar 

  • Crowe DL, Sinha UK . (2005). P53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines. Head Neck 21: 15–23.

    Google Scholar 

  • Dash BC, El-Deiry WS . (2005). Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25: 3364–3387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM, Schuuring E . (1995). Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 10: 1833–1840.

    CAS  PubMed  Google Scholar 

  • de Leeuw RJ, Davies JJ, Rosenwals A, Bbb G, Gascoyne RD, Dyer MJS et al. (2004). Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genetics 13: 1827–1837.

    Article  CAS  Google Scholar 

  • Elias B, Laine A, Ronai Z . (2005). Phosphorylation of MdmX by CDK2/Cdc2(p34) is required for nuclear export of Mdm2. Oncogene 24: 2574–2579.

    Article  CAS  PubMed  Google Scholar 

  • Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN et al. (2005). Mutually exclusive cyclin-dependent kinase 4/cyclin d1 and cyclin-dependent kinase 6/cyclin d2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 15: 11345–11353.

    Article  Google Scholar 

  • Ferbabdez V, Hartmann E, Ott G, Campo E, Rosenwald A . (2005). Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Onc 23: 6364–6369.

    Article  Google Scholar 

  • Fukuda T, Asai N, Enomoto A, Takahashi M . (2005). Activation of c-Jun amino-terminal kinase by GDNF induces G2/M cell cycle delay linked with actin reorganization. Genes Cells 10: 655–663.

    Article  CAS  PubMed  Google Scholar 

  • Gumireddy K, Pamana Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of PIK1, is a potent anticancer agent. Cancer Cell 7: 275–286.

    Article  CAS  PubMed  Google Scholar 

  • Hunter T, Pines J . (1994). Cyclins and cancer: II. Cyclin D and CDK inhibitors come of age. Cell 79: 573–582.

    Article  CAS  PubMed  Google Scholar 

  • Kimby E, Wallblom A, Sander B . (2005). Mantle cell lymphoma: Chromosomal aberrations, proliferation and cyclin D1 transcripts in relation to clinical outcome. Annals of Oncology 9th International Conference on Malignant Lymphoma 16 (Supplement 5): v168 (#446).

  • Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E . (2004). Mouse development and cell proliferation in the absence of D-cyclins. Cell 118: 477–491.

    Article  CAS  PubMed  Google Scholar 

  • Lardelli P, Bookman MA, Sundeen J, Longo DL, Jaffe ES . (1990). Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlation. Am J Surg Pathol 14: 752–763.

    Article  CAS  PubMed  Google Scholar 

  • Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L et al. (2001). Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Pro Natl Acad Sci USA 98: 3381–3386.

    Article  CAS  Google Scholar 

  • Martin SA, Ouchi T . (2005). BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis. Cancer Res 65: 100657–100662.

    Google Scholar 

  • Nevins JR, DeGregori J, Jakoi L, Leone G . (1997). Functional analysis of E2F transcription factor. Methods Enzymol 283: 205–219.

    Article  CAS  PubMed  Google Scholar 

  • Nozoe T, Takahashi I, Baba H, Maehara Y . (2005). Relationship between intracellular localization of p34cdc2 protein and differentiation of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131: 179–183.

    Article  CAS  PubMed  Google Scholar 

  • Park IW, Ulrich CK, Schoenberger E, Ganju RK, Groopman JE . (2001). HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 167: 2766–2771.

    Article  CAS  PubMed  Google Scholar 

  • Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK et al. (2005). Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGF-beta signaling pathways. Br J Haematol 130: 516–526.

    Article  CAS  PubMed  Google Scholar 

  • Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. (2003). The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185–197.

    Article  CAS  PubMed  Google Scholar 

  • Serrano M, Hannon GJ, Beach D . (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (London) 366: 704–707.

    Article  CAS  Google Scholar 

  • Sherr CJ, Roberts JM . (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.

    Article  CAS  PubMed  Google Scholar 

  • Sherr CJ, Roberts JM . (2004). Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699–2711.

    Article  CAS  PubMed  Google Scholar 

  • Swerdlow SH, Williams ME . (2002). From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 33: 7–20.

    Article  CAS  PubMed  Google Scholar 

  • Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q . (2005). Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cell. Cancer Res 65: 9012–9020.

    Article  CAS  PubMed  Google Scholar 

  • Tiemann M, Schrader C, Lkapper W, Dreyling MH, Campo E, Norton A et al. (2005). Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell clymphoma (MCL): a clinicopathological study form the European MCL Network. Br J Haematol 131: 29–38.

    Article  PubMed  Google Scholar 

  • Witzig TE . (2005). Current treatment approaches for mantle-cell lymphoma. J Clin Onc 23: 6409–6414.

    Article  CAS  Google Scholar 

  • Yamasaki L . (1998). Growth regulation by the E2F and DP transcription factor families. Results Probl Cell Differ 22: 199–227.

    Article  CAS  PubMed  Google Scholar 

  • Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al. (1995). Patterns of survival in mantle cell lymphoma. Ann Oncol 6: 257–262.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a charitable contribution from Henryk and Rochelle Schwarz. E Premkumar Reddy was supported by grant CA109820.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    I-W Park & J E Groopman

  2. Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, USA

    M V R Reddy & E P Reddy

Authors
  1. I-W Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M V R Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E P Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J E Groopman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J E Groopman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, IW., Reddy, M., Reddy, E. et al. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene 26, 5635–5642 (2007). https://doi.org/10.1038/sj.onc.1210350

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210350

Keywords

This article is cited by

Search

Advanced search

Quick links